Solr Search

MI made concrete improvements to pharmaceutical research and development (R&D); leveraging funding; creating new knowledge and tools; and making Europ

highly respected innovators— biopharmaceutical industry expert Bernard Munos and open science leader John Wilbanks— as senior fellows.

simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the

ulosis bacteria in their system.  Given the characteristics of airborne diseases like tuberculosis, coordination among national and international age

alled tau—a common culprit in a number of neurodegenerative diseases—we make the case that focused strategic investment in tau research and the , At present, no disease-modifying therapies for the pure tauopathies exist. Researchers are working to develop effective therapeutic agents, which include approaches such as decreasing the amount of tau within the brain., Symptomatic Interventions At present, no disease-modifying therapies for the pure tauopathies exist.

ers—the best of the best in sport, business, the military, the arts, and beyond?

reatments and cures?

As judged by patients' perspectives and experiences, how close are we to realizing this potential?

s of cancer—is a global trend that has seen a sharp rise in the MENA region.